SI1095037T2 - Postopek za pripravo 5-metoksi-2-((4-metoksi-3,5-dimetil-2-piridil)metil)sulfinil-1H- benzimidazola - Google Patents

Postopek za pripravo 5-metoksi-2-((4-metoksi-3,5-dimetil-2-piridil)metil)sulfinil-1H- benzimidazola

Info

Publication number
SI1095037T2
SI1095037T2 SI9930057T SI9930057T SI1095037T2 SI 1095037 T2 SI1095037 T2 SI 1095037T2 SI 9930057 T SI9930057 T SI 9930057T SI 9930057 T SI9930057 T SI 9930057T SI 1095037 T2 SI1095037 T2 SI 1095037T2
Authority
SI
Slovenia
Prior art keywords
methoxy
benzimidazole
pyridyl
dimethyl
methyl
Prior art date
Application number
SI9930057T
Other languages
English (en)
Other versions
SI1095037T1 (sl
Inventor
MILAČ Nataša HAFNER
Darja Jereb
Original Assignee
LEK, tovarna farmacevtskih in kemičnih izdelkov,d.d.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20432301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1095037(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LEK, tovarna farmacevtskih in kemičnih izdelkov,d.d. filed Critical LEK, tovarna farmacevtskih in kemičnih izdelkov,d.d.
Publication of SI1095037T1 publication Critical patent/SI1095037T1/sl
Publication of SI1095037T2 publication Critical patent/SI1095037T2/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B41/00—Formation or introduction of functional groups containing oxygen
    • C07B41/06—Formation or introduction of functional groups containing oxygen of carbonyl groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI9930057T 1998-07-13 1999-07-12 Postopek za pripravo 5-metoksi-2-((4-metoksi-3,5-dimetil-2-piridil)metil)sulfinil-1H- benzimidazola SI1095037T2 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SI9800196A SI20019A (sl) 1998-07-13 1998-07-13 Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
EP99930107A EP1095037B2 (en) 1998-07-13 1999-07-12 process of synthesis of 5-methoxy- 2- (4-methoxy- 3,5-dimethyl- 2-pyridyl)methyl|sulfinyl-1h-benzimidazole
PCT/SI1999/000020 WO2000002876A1 (en) 1998-07-13 1999-07-12 Improved process of synthesis of 5-methoxy- 2-[(4-methoxy- 3,5-dimethyl- 2-pyridyl)methyl]sulfinyl-1h-benzimidazole

Publications (2)

Publication Number Publication Date
SI1095037T1 SI1095037T1 (sl) 2002-08-31
SI1095037T2 true SI1095037T2 (sl) 2007-10-31

Family

ID=20432301

Family Applications (2)

Application Number Title Priority Date Filing Date
SI9800196A SI20019A (sl) 1998-07-13 1998-07-13 Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
SI9930057T SI1095037T2 (sl) 1998-07-13 1999-07-12 Postopek za pripravo 5-metoksi-2-((4-metoksi-3,5-dimetil-2-piridil)metil)sulfinil-1H- benzimidazola

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI9800196A SI20019A (sl) 1998-07-13 1998-07-13 Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola

Country Status (13)

Country Link
US (2) US6268502B1 (sl)
EP (1) EP1095037B2 (sl)
AT (1) ATE216382T1 (sl)
AU (1) AU4671499A (sl)
CZ (1) CZ293653B6 (sl)
DE (1) DE69901307D1 (sl)
HU (1) HUP0102523A2 (sl)
NZ (1) NZ509000A (sl)
PL (1) PL202167B1 (sl)
RU (1) RU2197486C2 (sl)
SI (2) SI20019A (sl)
SK (1) SK286432B6 (sl)
WO (1) WO2000002876A1 (sl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19951960C2 (de) * 1999-10-28 2002-06-27 Gruenenthal Gmbh Verfahren zur Herstellung als Ulkustherapeutika geeigneter Benzimidazol-Derivate
MXPA03006904A (es) 2001-02-02 2004-12-06 Teva Pharma Procesos para la produccion de 2-(2-piridilmetil) sulfinil - 1h - bencimidazoles sustituidos.
SI20875A (sl) 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
EP1409478B1 (en) 2001-07-16 2006-03-29 Janssen Pharmaceutica N.V. Improved process for preparing benzimidazole-type compounds
KR100873419B1 (ko) * 2002-06-18 2008-12-11 페어차일드코리아반도체 주식회사 높은 항복 전압, 낮은 온 저항 및 작은 스위칭 손실을갖는 전력용 반도체 소자
EP1764364A1 (en) * 2002-08-21 2007-03-21 Teva Pharmaceutical Industries Ltd A method for the purification of lansoprazole
AU2003258335A1 (en) * 2002-08-21 2004-03-11 Teva Pharmaceutical Industries Ltd. A method for the purification of lansoprazole
SE0203092D0 (en) 2002-10-18 2002-10-18 Astrazeneca Ab Method for the synthesis of a benzimidazole compound
EP1743893A1 (en) * 2002-11-18 2007-01-17 Teva Pharmaceutical Industries Ltd. Stable lansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol
EP1465890B1 (en) * 2002-11-18 2007-04-04 Teva Pharmaceutical Industries Ltd. Stable lansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol
US7678816B2 (en) * 2003-02-05 2010-03-16 Teva Pharmaceutical Industries Ltd. Method of stabilizing lansoprazole
PL1802584T3 (pl) * 2004-10-11 2010-03-31 Ranbaxy Laboratories Ltd Sposób wytwarzania podstawionych sulfotlenków
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
SE9002043D0 (sv) 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
SE521100C2 (sv) * 1995-12-15 2003-09-30 Astra Ab Förfarande för framställning av en bensimidazolförening
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole

Also Published As

Publication number Publication date
EP1095037A1 (en) 2001-05-02
WO2000002876A1 (en) 2000-01-20
EP1095037B1 (en) 2002-04-17
CZ2001123A3 (en) 2001-05-16
US6268502B1 (en) 2001-07-31
PL345543A1 (en) 2001-12-17
SK286432B6 (sk) 2008-10-07
SK252001A3 (en) 2001-07-10
PL202167B1 (pl) 2009-06-30
SI1095037T1 (sl) 2002-08-31
DE69901307D1 (de) 2002-05-23
AU4671499A (en) 2000-02-01
CZ293653B6 (cs) 2004-06-16
RU2197486C2 (ru) 2003-01-27
SI20019A (sl) 2000-02-29
US20020007069A1 (en) 2002-01-17
EP1095037B2 (en) 2007-08-08
HUP0102523A2 (hu) 2001-11-28
ATE216382T1 (de) 2002-05-15
NZ509000A (en) 2001-12-21

Similar Documents

Publication Publication Date Title
SI1095037T2 (sl) Postopek za pripravo 5-metoksi-2-((4-metoksi-3,5-dimetil-2-piridil)metil)sulfinil-1H- benzimidazola
EP0997461A4 (en) PROCESSES FOR THE PREPARATION OF PYRIDINIC DERIVATIVES
HK1123985A1 (en) Amorphous (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2- pyridinyl]methyl]sulfinyl]-1h-benzimidazole as anti-ulcer agent
WO1998054171A8 (en) Novel form of s-omeprazole
UA32524C2 (uk) Спосіб одержання омепразолу
ATE160783T1 (de) Gallensäurederivate, verfahren zu ihrer herstellung und verwendung dieser verbindungen als arzneimittel
ATE302754T1 (de) Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
MY111737A (en) Use of omeprazole as an antimicrobial agent.
AU6350699A (en) Chemical compounds
MY119095A (en) Potassium salt of (s)-omeprazole
YU31199A (sh) Novi postupak
DE3768658D1 (de) 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
IL158561A0 (en) Crystalline form of omerprazole
ES2023609A6 (es) Procedimiento para la obtencion del 2-(((3-metil -4-(2,2,2-trifluoroetoxi) -2-piridinil) metilisulfinil) -1h-bemzimidazol.
RU2001103900A (ru) Усовершенствованный способ синтеза 5-метокси-2-[(4-метокси-3,5-диметил-2-пиридил)метил]сульфинил-1н-бензимидазола
ES2060541A1 (es) Nuevo procedimiento para la sintesis de un derivado de 2-(2-piridilmetilsufinil) bencimidazol, y nuevos productos intermedios obtenidos con el mismo.
ATE267809T1 (de) Substituierte 1,3-diaryl-2-pyridin-2-yl-3- (pyridin-2-ylamino)-propanolderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DE50104557D1 (de) Neue beta-amyloid inhibitoren, verfahren zu deren herstellung und deren verwendung als arzneimittel
HUP9903744A2 (hu) Eljárás omeprazol előállítására
ES2063705A1 (es) Intermedio para la sintesis de lansoprazol y su procedimiento de obtencion.
ATE224890T1 (de) Substituierte 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin- 0-ole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
HUP0002258A3 (en) Process for manufacturing n-alk(en)oxy (or aryloxy)carbonyl)- isothiocyanate derivatives in the presence of n,n-dialkylarylamine catalyst
ES2036502A6 (es) Mejoras en el objeto de la patente n{ 9003113 por procedimiento de obtencion de halohidrato de 2-halometil-3,5-dimetil-4-metoxipiridina.